S100β as a serum marker in endocrine resistant breast cancer

BACKGROUND: Endocrine therapy is standard treatment for estrogen receptor (ER)-positive breast cancer. However, its efficacy is limited by intrinsic and acquired resistance. Here the potential of S100β as a biomarker and inhibition of its signaling network as a therapeutic strategy in endocrine trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Charmsaz, Sara, Hughes, Éamon, Bane, Fiona T., Tibbitts, Paul, McIlroy, Marie, Byrne, Christopher, Cocchiglia, Sinéad, McBryan, Jean, Hennessy, Bryan T., Dwyer, Róisín M., Kerin, Michael J., Hill, Arnold D., Young, Leonie S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389184/
https://www.ncbi.nlm.nih.gov/pubmed/28399921
http://dx.doi.org/10.1186/s12916-017-0836-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389184/
https://www.ncbi.nlm.nih.gov/pubmed/28399921
http://dx.doi.org/10.1186/s12916-017-0836-2

Ejemplares similares